BRCA2 and cancer: Furthermore, identifying other non-CRC/polyposis associated clinically actionable genes, such as PGVs in BRCA1 or BRCA2 which were identified in 0.44% and 0.55% of our cohort, respectively, confer potential eligibility for PARP inhibitor clinical treatment trials and can have substantial, and possibly lifesaving, implications for cancer risk management for both patients and their families.